ArticleClinical epigenetics2018
A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma.
Article in Clinical epigenetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 54 citations in OpenAlex.
- Development and validation of a 5mC-based prognostic model for lung adenocarcinoma survival.Cell reports. Medicine · 2026Article
- The gene panel with methylation-related genes and clinical factors for predicting overall survival of endometrial cancer.Journal of medical biochemistry · 2025Article
- The Role of Methylation in Ferroptosis.Journal of cardiovascular translational research · 2024Review
- Article
- Cuproptosis-related gene-located DNA methylation in lower-grade glioma: Prognosis and tumor microenvironment.Cancer biomarkers : section A of Disease markers · 2024Article
- A DNA methylation signature for the prediction of tumour recurrence in stage II colorectal cancer.British journal of cancer · 2023Article
- A novel DNA methylation-related gene signature for the prediction of overall survival and immune characteristics of ovarian cancer patients.Journal of ovarian research · 2023Article
- Risk model-guided identification of MTDH expression as a marker for ferroptosis induction therapy in head and neck squamous cell carcinoma.American journal of cancer research · 2023Article
- Identification and Validation of Ferroptosis-Related DNA Methylation Signature for Predicting the Prognosis and Guiding the Treatment in Cutaneous Melanoma.International journal of molecular sciences · 2022Article
- Identification and validation of a gene-based signature reveals SLC25A10 as a novel prognostic indicator for patients with ovarian cancer.Journal of ovarian research · 2022Article
- Ferroptosis-associated DNA methylation signature predicts overall survival in patients with head and neck squamous cell carcinoma.BMC genomics · 2022Article
- Integration of Transcriptome and Epigenome to Identify and Develop Prognostic Markers for Ovarian Cancer.Journal of oncology · 2022Article
- Methylation-based reclassification and risk stratification of skull-base chordomas.Frontiers in oncology · 2022Article
- DNA methylation alterations caused byFrontiers in cellular and infection microbiology · 2022Review
- Identification of a glycolysis-related gene signature for survival prediction of ovarian cancer patients.Cancer medicine · 2021Article
- Heat shock proteins with an emphasis on HSP 60.Molecular biology reports · 2021Review
- Identification of a methylomics-associated nomogram for predicting overall survival of stage I-II lung adenocarcinoma.Scientific reports · 2021Article
- Development of a novel transcription factors-related prognostic signature for serous ovarian cancer.Scientific reports · 2021Article
- Association of variably methylated tumour DNA regions with overall survival for invasive lobular breast cancer.Clinical epigenetics · 2021Article
- Expression scoring of a small-nucleolar-RNA signature identified by machine learning serves as a prognostic predictor for head and neck cancer.Journal of cellular physiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOvarian cancer is the most fatal tumor of the female reproductive system and the fifth leading cause of cancer death among women in the USA. The prognosis is poor due to the lack of biomarkers for treatment options.
resultsThe methylation array data of 551 patients with ovarian serous cystadenocarcinoma (OSC) in The Cancer Genome Atlas (TCGA) database were assessed in this study to explore the methylation biomarkers associated with prognosis and improve the prognosis of patients. These patients were divided into training (first two thirds) and validation datasets (remaining one third). A five-DNA methylation signature was found to be significantly associated with the overall survival of patients with OSC using the Cox regression analysis in the training dataset. The Kaplan-Meier analysis showed that the five-DNA methylation signature could significantly distinguish the high- and low-risk patients in both training and validation sets. The receiver operating characteristic (ROC) analysis further confirmed that the five-DNA methylation signature exhibited high sensitivity and specificity to predict the prognostic survival of patients. Also, the five-DNA methylation signature was not only applicable in patients of different ages, stages, histologic grade, and size of residual tumor after surgery but also more accurate in predicting OSC prognosis compared with known biomarkers.
conclusionsThis five-DNA methylation signature demonstrated the potential of being a novel independent prognostic indicator and served as an important tool for guiding the clinical treatment of OSC to improve outcome prediction and management for patients. Hence, the findings of this study might have potential clinical significance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.